

Introducing Diabetes Reviews

Imagine going to a seminar with the world's leading diabetes investigators ... without leaving your office

If you're like the average clinician treating diabetes, you probably have a tough time keeping up with all of the latest basic and clinical diabetes research. *Diabetes Reviews*, the new quarterly review journal from the American Diabetes Association, can help. In its pages, top investigators discuss their latest findings, explain how they relate to previous data, and point out the clinical significance of the work. Each issue is like completing a postgraduate course in diabetes.

Contributors are chosen to offer the broadest possible perspective on a given subject. *Diabetes Reviews* will cover the topics that clinicians face most often, including:

- complications of IDDM and NIDDM
- methods of achieving and effects of good glycemic control
- drug treatment, including mechanism of action
- exercise therapy
- management of lipid disorders
- epidemiology of diabetes and its complications
- and much more

Edited by noted diabetes investigator Ralph DeFronzo of the University of Texas, *Diabetes Reviews* will bring you to the frontiers of diabetes research. It is a must read for any clinician who wants to keep up-to-date on the most quickly advancing areas of clinical and basic research.

✂.....

Please begin my charter subscription to *Diabetes Reviews*. * My payment of \$65 is enclosed. (Nonmember rate is \$85.)

Name/Degree: _____

Address: _____

City: _____ State: _____ Zip: _____

J42DCDR1

Return this form with payment to: American Diabetes Association
Professional Journal Subscriptions
1660 Duke Street
Alexandria, VA 22314

Method of payment:

[] Check or money order [] VISA [] MasterCard [] American Express

Card #: _____

Exp Date: _____

Signature: _____

* *Diabetes Reviews* begins quarterly publication with the March 1993 issue. All orders must be paid in US funds, drawn on a US bank. Canadians add 7% GST tax.

Diabetic Medicine

Journal of the British Diabetic Association

EDITORIAL

- Cohorts of Insulin-treated Patients with Diabetes** A. J. Sverdlow 894

REVIEW

- Gestational Diabetes: A Challenge for the Future** A. Dornhorst, R. W. Beard 897

ORIGINAL ARTICLES

- Does the Prepubertal Duration of Diabetes Influence the Onset of Microvascular Complications?**
P. G. McNally, N. T. Raymond, P. G. F. Switt, J. R. Hearnshaw, A. C. Burden 906

- Abnormal Digital Pressure Measurements in Diabetic Neuropathic Foot Ulceration** M. J. Stevens,
D. E. Goss, A. V. M. Foster, D. Pitei, M. E. Edmonds, P. J. Watkins 909

- Changes in Autonomic Nervous Function over a 5-Year Period in Non-insulin-dependent Diabetic Patients** R. Quadri, P. Ponzani, M. Zanone, S. Maule, A. La Grotta, G. Papotti, M. Valentini, C. Matteoda,
L. Chiandussi, D. Fonzo 916

- Prevalence of QT Prolongation in a Type 1 Diabetic Population and Its Association with Autonomic Neuropathy** R. Sivieri, M. Veglio, A. Chinaglia, L. Scaglione, P. Cavallo-Perin for the Neuropathy Study Group of the Italian Society for the Study of Diabetes, Piemonte Affiliate 920

- The Toxic Effects of Serum from Patients with Type 1 Diabetes Mellitus on Mouse Neuroblastoma Cells: A New Mechanism for Development of Diabetic Autonomic Neuropathy** G. L. Pittenger, D. Liu, A. I. Vinik 925

- Reproducibility of Parameters for Assessment of Diabetic Neuropathy** P. Valensi, J.-R. Attali, S. Gagant and the French Group for Research and Study of Diabetic Neuropathy 933

- Physiological, Symptomatic and Hormonal Responses to Acute Hypoglycaemia in Type 1 Diabetic Patients with Autonomic Neuropathy** D. A. Hepburn, K. M. MacLeod, B. M. Frier 940

- Different Acute and Chronic Effects of Acipimox Treatment on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes** C. Saloranta, L. Groop, A. Ekstrand, A. Franssila-Kallunki, J. Eriksson, M.-R. Taskinen 950

- Wine for Type 2 Diabetes?** C. Christiansen, C. Thomsen, O. Rasmussen, M. Balle, C. Hauerslev, C. Hansen, K. Hermansen 958

- Prescribed Versus Unrestricted Carbohydrate Diets in Children with Type 1 Diabetes** K. J. Price, J. D. Lang, C. Eiser, J. H. Tripp 962

CLINICAL PRACTICE

- What do People with Diabetes Want to Talk About With Their Doctors?** I. J. Benett 968

- Pre-mixed Insulin Delivered by Disposable Pen in the Management of Children with Diabetes**
M. O'Hagan, S. A. Greene 972

- Evaluation of Glycaemic Control Limits Using the Ames DCA 2000 HbA_{1c} Analyser** A. G. Rumley, E. S. Kilpatrick, M. H. Dominiczak, M. Small 976

CASE REPORT

- Alternative Medicine: Potential Dangers for the Diabetic Foot** D. L. Ewins, K. Bakker, M. J. Young, A. J. M. Boulton 980

LIVING WITH DIABETES

- Education and Employment for Young People with Diabetes** N. Robinson, L. K. Stevens, L. E. Protopapa 983

WORKING PARTY REPORT

- Consensus Guidelines for the Management of Insulin-dependent (Type 1) Diabetes** European IDDM Policy Group 990

LETTERS

- Diabetes Mellitus and Employment** R. G. Moses, R. Griffiths 1006

- Diabetes Mellitus and Employment Discrimination** R. G. Moses, R. Griffiths 1006

Forthcoming Papers, 892 • DM Diary, 893 • Media Review, 1007 • 'Diabetes Care' Contents Page, 1008 • Author Index, 1009 • Keyword Index, 1012 • Volume Contents, 1014



0742-3071(199312)10:10;1-2




WILEY

A WILEY MEDICAL PUBLICATION

DIMEEV 10(10) 889-1024 (1993)

ISSN 0742-3071

Diabetes patients reap the benefits when you plant the seeds of risk reduction.



Just as four-o'clock flowers open with regularity each day, regular blood glucose testing opens the way to lowering the risk of diabetes complications.

Frequent testing facilitates intensive control

The landmark Diabetes Control and Complications Trial (DCCT) concluded that intensive therapy reduces the long-term complications of diabetes. And frequent blood glucose determinations are a critical element of intensive therapy.


Self-monitoring provides an easy and reliable way to check blood glucose levels throughout the day. At physician office visits and in hospitals, laboratory blood glucose testing remains an important indicator of glycemic control, especially for patients who are just beginning to self-monitor.



Just as the flowers of the morning glory appear before the blooms of many other plants, fructosamine testing provides an early indication of glycemic control.

Monthly testing indicates early treatment response

Fructosamine testing provides an interim measurement of glycemic control to complement daily blood glucose testing and quarterly measurements of hemoglobin A_{1c}. Fructosamine reflects glycemic control over a 2 to 3 week period, so that evidence of hyperglycemic episodes is known within a month of their occurrence. Fructosamine's faster indication of response makes it a valuable enhancement to intensive patient management.



Changing seasons are reflected in the growth stages of the strawberry plant, just as the need for changes in treatment can be reflected by HbA_{1c} testing.

Quarterly testing signals need for adjustments

The ADA recommends testing hemoglobin A_{1c} every three months. Since HbA_{1c} values reflect average blood glucose over 60 to 90 days, fluctuations during this period can produce an elevated HbA_{1c} result. The DCCT study indicates that the progression of diabetes complications is greater when HbA_{1c} is elevated. Quarterly testing can signal the need for therapeutic intervention to reduce this risk.



As easy as it is to include kidney beans in a healthy diet, monitoring kidney health is equally easy through microalbuminuria testing.


Annual screening detects treatable nephropathy

The DCCT finding that intensive therapy reduces the risk of kidney damage supports the ADA recommendation for annual microalbuminuria (MAU) screening beginning five years after diagnosis. Early detection can identify patients in whom progression to nephropathy may be slowed through intensive therapy.

Boehringer Mannheim provides complete diabetes profiling reagents and instruments with laboratory reliability and accuracy. Blood glucose testing systems and microalbuminuria test strips further support quality care. Plant the seeds of reduced complications through tests to guide diabetes therapy. For more information, call 1-800-428-5030.

MILES

Recommend the new standard for simplicity.



Actual Size

No buttons...no bother!

With the GLUCOMETER ELITE Diabetes Care System, there are no buttons to push, no test strips to wipe or blot. Your patients just insert the GLUCOMETER ELITE Test Strip to activate the meter, touch blood to the tip of the strip, and read the results in 60 seconds. Even the right amount of blood is determined automatically. And less blood is required than for any other blood glucose meter.

No wonder three out of four people surveyed gave the GLUCOMETER ELITE System an overall rating of "excellent" or "very good."* It's the first system for diabetes self care that's more than technique-independent. It's virtually technique-free.

The GLUCOMETER ELITE System comes with everything your patients need to start blood glucose testing. For more information, contact your Miles Inc., Diagnostics Division representative, or call toll-free 1-800-445-5901.

*Data on file, Miles Inc.

GLUCOMETER ELITE™ Diabetes Care System

The meter designed with your patients in mind.

MILES 
Diagnostics Division
Miles Inc.
Tarrytown, NY 10591